Sensus Healthcare, Inc.
NASDAQ:SRTSMedical - Devices
+$0.09 today
- Market cap
- $53.01M
- Beta
- 1.09
- P/E (TTM)
- -6.5
- EPS (TTM)
- -$0.47
Volume 0.08M
Average 0.06M
SRTS Gross Margin
Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.
Sensus Healthcare, Inc.NASDAQ: SRTS
Gross Margin · Q1 FY2026 · quarter ended Mar 2026
Gross margin narrows to 29.2%
Gross margin was 29.2% in Q1 FY2026, down 23.0 pp from a year earlier. On a trailing-twelve-month basis it was 37.7%, down 18.3 pp year over year. Over 3 fiscal years it narrowed by 23.4 pp.
Context
- Gross margin widened in 1 of the last 3 fiscal years.
- FY2025 was the lowest level in the 4 fiscal years shown.
Sources:Income StatementText generated from reported figures; not investment advice.
Gross Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 43.2%
- Year-over-year change
- -15.3pp
| Period | Period end | Gross Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 43.2% | -15.3pp |
| FY2024 | 2024-12-31 | 58.4% | +0.8pp |
| FY2023 | 2023-12-31 | 57.6% | -8.9pp |
| FY2022 | 2022-12-31 | 66.5% | +3.7pp |
| FY2021 | 2021-12-31 | 62.8% | — |
Gross Margin vs competitors
How SRTS compares with its peers on the latest reported figures
- SRTS's LTM Mar 2026 gross margin of 37.7% is the lowest of the 6 companies compared; the peer median is 83.8%.
- Its year-over-year change of -18.3 pp is the lowest of 6, against a peer median of -0.3 pp.
- Over three fiscal years its change of -23.4 pp compares with a peer median of +2.4 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 96.0% | -0.1 pp | -0.8 pp | |
| FY2025 | 88.0% | -12.0 pp | -12.0 pp | |
BDMDBaird Medical Investment Holdings Limited | FY2025 | 83.8% | -4.4 pp | +3.9 pp |
| LTM Jun 2026 | 67.8% | +0.5 pp | +2.4 pp | |
MDAISpectral AI, Inc. | LTM Mar 2026 | 44.7% | -0.3 pp | +2.7 pp |
| LTM Mar 2026 | 37.7% | -18.3 pp | -23.4 pp | |
| Peer median (excluding SRTS) | 83.8% | -0.3 pp | +2.4 pp | |
Competitors are the stored peer set for SRTS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 27.04M | 44.53M | 24.41M | 41.81M | 27.48M |
| Cost of Revenue | 10.05M | 14.9M | 10.35M | 17.38M | 15.62M |
| Gross Profit | 16.99M | 29.63M | 14.06M | 24.43M | 11.87M |
| Gross Margin | 62.8% | 66.5% | 57.6% | 58.4% | 43.2% |
| Research & Development | 3.44M | 3.46M | 3.68M | 4.22M | 7.78M |
| Selling, General & Admin | 9.43M | 11.34M | 10.76M | 12.13M | 14.4M |
| Operating Expenses | 12.87M | 14.8M | 14.44M | 16.34M | 22.17M |
| Depreciation & Amortization | 613K | 509K | 461K | 432K | 386K |
| EBITDA | 4.73M | 28.5M | 1.11M | 9.45M | (9.24M) |
| EBITDA Margin | 17.5% | 64.0% | 4.6% | 22.6% | -33.6% |
| Operating Income | 4.12M | 14.83M | (382K) | 8.09M | (10.31M) |
| Operating Margin | 15.2% | 33.3% | -1.6% | 19.4% | -37.5% |
| Interest Income | 2K | 382K | 992K | 932K | 683K |
| Interest Expense | 1K | 2K | 0 | 0 | 0 |
| Other Income / Expenses | (1K) | 13.16M | 1.03M | 932K | 683K |
| Income Before Tax | 4.12M | 27.99M | 652K | 9.02M | (9.62M) |
| Pre-Tax Margin | 15.2% | 62.9% | 2.7% | 21.6% | -35.0% |
| Income Tax Expense | 0 | 3.75M | 167K | 2.38M | (1.91M) |
| Net Income | 4.12M | 24.24M | 485K | 6.65M | (7.72M) |
| Net Margin | 15.2% | 54.4% | 2.0% | 15.9% | -28.1% |
| EPS (Basic) | 0.25 | 1.47 | 0.03 | 0.41 | (0.47) |
| EPS (Diluted) | 0.25 | 1.46 | 0.03 | 0.41 | (0.47) |
| Weighted Avg Shares | 16.48M | 16.48M | 16.26M | 16.31M | 16.33M |
| Weighted Avg Shares (Diluted) | 16.5M | 16.62M | 16.27M | 16.36M | 16.33M |
Sensus Healthcare, Inc.
NASDAQ:SRTS
Intrinsic Alpha fair value
Locked
Current Price
$3.22
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.